Kyntra Bio, Inc. (KYNB)
KYNB Stock Price Chart
Explore Kyntra Bio, Inc. interactive price chart. Choose custom timeframes to analyze KYNB price movements and trends.
KYNB Company Profile
Discover essential business fundamentals and corporate details for Kyntra Bio, Inc. (KYNB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
14 Nov 2014
Employees
225.00
Website
https://www.kyntrabio.comCEO
Thane Wettig
Description
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Financial Timeline
Browse a chronological timeline of Kyntra Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$3.18, while revenue estimate is $2.09m.
Earnings released on 11 May 2026
EPS came in at -$3.74 falling short of the estimated -$3.36 by -11.31%, while revenue for the quarter reached $3.70m , beating expectations by +137.94%.
Earnings released on 16 Mar 2026
EPS came in at -$3.61 surpassing the estimated -$3.89 by +7.20%, while revenue for the quarter reached $1.30m , missing expectations by -22.16%.
Earnings released on 10 Nov 2025
EPS came in at -$1.61 surpassing the estimated -$4.01 by +59.85%, while revenue for the quarter reached $1.08m , missing expectations by -35.57%.
Earnings released on 11 Aug 2025
EPS came in at -$3.38 falling short of the estimated -$2.25 by -50.22%, while revenue for the quarter reached $1.35m , missing expectations by -53.52%.
Stock split effective on 17 Jun 2025
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2025
EPS came in at -$4.00 falling short of the estimated $0.75 by -633.33%, while revenue for the quarter reached $2.74m , beating expectations by +36.95%.
Earnings released on 17 Mar 2025
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached -$123.26m , missing expectations by -594.81%.
Earnings released on 12 Nov 2024
EPS came in at -$0.17 surpassing the estimated -$0.38 by +55.26%, while revenue for the quarter reached $46.33m , beating expectations by +129.09%.
Earnings released on 6 Aug 2024
EPS came in at -$0.16 surpassing the estimated -$0.26 by +38.46%, while revenue for the quarter reached $50.64m , beating expectations by +46.11%.
Earnings released on 6 May 2024
EPS came in at -$0.33 falling short of the estimated -$0.31 by -6.45%, while revenue for the quarter reached $55.90m , beating expectations by +52.45%.
Earnings released on 26 Feb 2024
EPS came in at -$0.57 falling short of the estimated -$0.42 by -35.71%, while revenue for the quarter reached $27.14m , missing expectations by -30.24%.
Earnings released on 6 Nov 2023
EPS came in at -$0.52 surpassing the estimated -$0.68 by +23.53%, while revenue for the quarter reached $40.13m , beating expectations by +2.15%.
Earnings released on 7 Aug 2023
EPS came in at -$0.65 surpassing the estimated -$0.72 by +9.72%, while revenue for the quarter reached $44.32m , beating expectations by +27.57%.
Earnings released on 8 May 2023
EPS came in at -$0.81 falling short of the estimated -$0.76 by -6.58%, while revenue for the quarter reached $36.16m , beating expectations by +13.57%.
Earnings released on 27 Feb 2023
EPS came in at -$0.70 surpassing the estimated -$0.95 by +26.32%, while revenue for the quarter reached $34.37m , beating expectations by +43.38%.
Earnings released on 7 Nov 2022
EPS came in at -$0.98 falling short of the estimated -$0.83 by -18.07%, while revenue for the quarter reached $15.74m , missing expectations by -50.24%.
Earnings released on 8 Aug 2022
EPS came in at -$0.78 surpassing the estimated -$0.94 by +17.02%, while revenue for the quarter reached $29.81m , missing expectations by -17.57%.
Earnings released on 9 May 2022
EPS came in at -$0.68 surpassing the estimated -$0.84 by +19.05%, while revenue for the quarter reached $60.83m , beating expectations by +111.51%.
Earnings released on 28 Feb 2022
EPS came in at -$1.45 falling short of the estimated -$0.68 by -113.24%, while revenue for the quarter reached $16.54m , missing expectations by -65.28%.
Earnings released on 9 Nov 2021
EPS came in at $0.54 surpassing the estimated $0.01 by +9.10k%, while revenue for the quarter reached $155.97m , beating expectations by +17.34%.
Earnings released on 9 Aug 2021
EPS came in at -$1.45 falling short of the estimated -$0.48 by -202.08%, while revenue for the quarter reached $24.36m , missing expectations by -64.73%.
KYNB Stock Performance
Access detailed KYNB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
